Clinical-stage biotechnology company Tectonic Therapeutic Inc. (TECX) is building its pipeline around a single, urgent truth: pulmonary hypertension doesn't wait. It progresses quietly, often masked by fatigue or shortness of breath, until the body can no longer compensate. For patients with interstitial lung disease or heart failure, the stakes are immediate, and the options are limited.
TX45 is being developed to meet that moment. Not as a theoretical solution, but as a candidate already showing signs of impact.
For comments and feedback contact: editorial@rttnews.com
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.